Premium
IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL
Author(s) -
Cramer P.,
Demirkan F.,
Fraser G.,
Pristupa A.,
Bartlett N.,
Dilhuydy M.,
Loscertales J.,
Avigdor A.,
Rule S.,
Samoilova O.,
Goy A.,
Ganguly S.,
Poggesi I.,
Lavezzi S.M.,
De Nicolao G.,
Jong J.,
Neyens M.,
Salman M.,
Howes A.,
Mahler M.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_95
Subject(s) - ibrutinib , bendamustine , medicine , pharmacokinetics , rituximab , nonmem , placebo , pharmacology , lymphoma , gastroenterology , chronic lymphocytic leukemia , leukemia , pathology , alternative medicine